Albireo Pharma Revenue and Competitors

Boston, MA USA

Location

$40M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Albireo Pharma's estimated annual revenue is currently $24.2M per year.(i)
  • Albireo Pharma's estimated revenue per employee is $193,440
  • Albireo Pharma's total funding is $40M.

Employee Data

  • Albireo Pharma has 125 Employees.(i)
  • Albireo Pharma grew their employee count by -22% last year.

Albireo Pharma's People

NameTitleEmail/Phone
1
VP Pharmaceutical DevelopmentReveal Email/Phone
2
VP, Global Commercial AnalyticsReveal Email/Phone
3
SVP, Global Head Medical AffairsReveal Email/Phone
4
VP Translational ScienceReveal Email/Phone
5
Associate General Counsel and Chief Compliance OfficerReveal Email/Phone
6
VP, Manufacturing OperationsReveal Email/Phone
7
SVP, Global Market AccessReveal Email/Phone
8
Senior Director, Medical Science LiaisonReveal Email/Phone
9
Director, Clinical OperationsReveal Email/Phone
10
Reimbursement & Patient Access Director, U.S.Reveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Albireo Pharma?

Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo's lead product candidate, A4250, is directed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis. Albireo's clinical pipeline also includes two Phase 2 product candidates. Albireo's elobixibat, approved in Japan for the treatment of chronic constipation, is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world. Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.

keywords:N/A

$40M

Total Funding

125

Number of Employees

$24.2M

Revenue (est)

-22%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Albireo Pharma News

2022-04-19 - Albireo Pharma, Inc. (NASDAQ:ALBO) Short Interest Down ...

Albireo Pharma, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid...

2022-04-19 - Investing in Albireo Pharma (NASDAQ:ALBO) five years ago would have delivered you a 57% gain

Given that Albireo Pharma didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business...

2022-03-22 - No small feat': Albireo CEO talks biotech's commercial ...

Last September, the FDA blessed Mirum Pharmaceuticals' Livmarli as the first treatment for Alagille syndrome. Mirum also is testing the drug in PFIC and biliary...

2021-11-16 - Albireo Pharma : Post-AASLD Business Update

Post-AASLD Business Update November 16, 2021 (Nasdaq: ALBO) For Media & Investors Only ©2021 Albireo Pharma, Inc. All rights reserved Forward Looking Statements This presentation includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 19 ...

2021-10-12 - CBC-backed Jadeite Medicines Announces Exclusive Licensing Agreement with Albireo Pharma to Develop and Promote Odevixibat in Japan

TOKYO, Oct. 12, 2021 /PRNewswire/ -- Jadeite Medicines Inc. ("Jadeite"), a biopharmaceutical company that is backed by Singapore's CBC Group ("CBC") and committed to addressing critical unmet medical needs for patients in Japan, today entered into an exclusive licensing agreement with Albireo Ph ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$37.5M125-5%$200.4M
#2
$7.5M12513%N/A
#3
$18.1M12528%$30M
#4
$26.3M1254%N/A
#5
$22.5M12523%N/A